Healthcare and telemedicine provider secures $32 million in funding

Digital healthcare and telemedicine provider Zava has secured $32 million in Series A investment ahead of its launch into statutory healthcare systems in Germany, UK and France in a funding round led by HPE Growth.

Since 2011, Zava has provided 3 million paid consultations across six markets in Europe, of which 1 million were in 2018. Every month almost 100,000 patients access Zava from the UK, Germany, France, Austria, Switzerland and Ireland to seek advice, tests or treatment for a range of conditions.

David Meinertz, Zava co-founder and CEO said: “In a world of an ageing population and rising costs, healthcare systems are at a breaking point. Barriers are put in people’s way and stop them getting the support they need. Zava exists to break down these barriers – costs, access & information. Enabling people to do more of what matters to them. We’re pleased that our new partners at HPE Growth share that great ambition. Zava’s mission is to build healthcare that is accessible, dependable and a fraction of today’s cost.”

Zava will use the investment to further accelerate its growth including building out its team in order to expand its medical offering. The funding will also help to expand Zava’s business in existing markets and to grow pan-European and then globally.

Harry Dolman, partner at HPE Growth, said: “Zava offers a unique and highly scalable model to deliver a more convenient healthcare experience to patients while radically improving the efficiency of healthcare professionals, enabling healthcare systems to reduce the overall costs associated with primary care. We are excited to be working with David and his team to expand Zava into statutory healthcare systems and bring Zava in a first step to the rest of Europe.”



About


'Healthcare and telemedicine provider secures $32 million in funding' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2019 Rapid Life Sciences Ltd, a Rapid News Group Company. All Rights Reserved.

Privacy policy

Terms and conditions